Ranbaxy Blocked From Copying Schering's Clarinex

Law360, New York (August 30, 2007, 12:00 AM EDT) -- Schering-Plough Corp. has won a boost in its battle to protect Clarinex, with a federal judge issuing a permanent injunction barring Indian generic drug maker Ranbaxy Laboratories Ltd. from manufacturing or selling a copycat version of the allergy medication until the life of the patent expires.

U.S. District Judge Mary L. Cooper handed down the consent judgment and order on Tuesday in the U.S. District Court for the District of New Jersey. Both Schering and Ranbaxy stipulated the terms of the injunction in April.

The order...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.